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Abstract
Background: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Clinically, AD is
characterized by impairments of memory and cognitive functions. Accumulation of amyloid-β (Aβ) and neurofibrillary
tangles are the prominent neuropathologies in patients with AD. Strong evidence indicates that an imbalance between
production and degradation of key proteins contributes to the pathogenesis of AD. The mammalian target of rapamycin
(mTOR) plays a key role in maintaining protein homeostasis as it regulates both protein synthesis and degradation. A key
regulator of mTOR activity is the proline-rich AKT substrate 40 kDa (PRAS40), which directly binds to mTOR and reduces
its activity. Notably, AD patients have elevated levels of phosphorylated PRAS40, which correlate with Aβ and tau
pathologies as well as cognitive deficits. Physiologically, PRAS40 phosphorylation is regulated by Pim1, a protein kinase
of the protoconcogene family. Here, we tested the effects of a selective Pim1 inhibitor (Pim1i), on spatial reference and
working memory and AD-like pathology in 3xTg-AD mice.
Results: We have identified a Pim1i that crosses the blood brain barrier and reduces PRAS40 phosphorylation.
Pim1i-treated 3xTg-AD mice performed significantly better than their vehicle treated counterparts as well as
non-transgenic mice. Additionally, 3xTg-AD Pim1i-treated mice showed a reduction in soluble and insoluble
Aβ40 and Aβ42 levels, as well as a 45.2 % reduction in Aβ42 plaques within the hippocampus. Furthermore,
phosphorylated tau immunoreactivity was reduced in the hippocampus of Pim1i–treated 3xTg-AD mice by
38 %. Mechanistically, these changes were linked to a significant increase in proteasome activity.
Conclusion: These results suggest that reductions in phosphorylated PRAS40 levels via Pim1 inhibition reduce
Aβ and Tau pathology and rescue cognitive deficits by increasing proteasome function. Given that Pim1
inhibitors are already being tested in ongoing human clinical trials for cancer, the results presented here may
open a new venue of drug discovery for AD by developing more Pim1 inhibitors.
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Background
Alzheimer’s disease (AD) is the most prevalent neurode-
generative disorder worldwide. Clinically, AD is charac-
terized by impairments of memory, cognitive and
intellectual functions [1]. The buildup of amyloid-β (Aβ)
plaques and neurofibrillary tangles (NFTs) are the two
prominent pathologies contributing to the progression
of cognitive deficits in AD [2]. Aβ is generated from the
amyloid precursor protein (APP), which is sequentially
cleaved by the β-site APP cleaving enzyme 1 (BACE-1)
and the γ-secretase complex to liberate Aβ. NFTs
consist of hyperphosphorylated and aggregated tau, a
microtubule-binding protein. Over the next few decades,
advancing age of the global population will dramatically
increase the prevalence of AD to an estimated 20 million
by 2050 in the US alone [3]. Currently, there are no
effective treatment options to either prevent or re-
duce the progression of AD. Therefore, there is an
urgent need for novel, safe, and efficacious strategies
to mitigate this disorder.
Aging is the most important risk factor for AD; thus,
it is possible that altered signaling pathways associated
with aging may facilitate the development of AD and
other age-dependent disorders [4, 5]. Overwhelming
evidence has shown that the mammalian target of
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rapamycin (mTOR), a serine/threonine protein kinase
involved in the regulation of protein synthesis and deg-
radation, plays a key role in regulating lifespan and
health span [5–7]. mTOR is part of two major com-
plexes, the mTOR complex 1 (mTORC1) and 2
(mTORC2), which have different functions [8, 9].
mTOR signaling is upregulated in AD [10–13]. To
this end, we and others have shown that reducing
mTOR activity pharmacologically, with rapamycin, or
genetically ameliorates Aβ plaque load and NFTs while
improving cognitive deficits in multiple animal models of
AD [10, 14–17]. However, various studies have found
that rapamycin has many side effects, necessitating
other treatment options to reduce mTOR hyperactivity
in AD [18–20].
The proline-rich Akt substrate 40 kDa (PRAS40) is a
constituent of the mTORC1, which physically binds to
mTOR and inhibits its activity. Upon phosphorylation at
Thr246 by serine/threonine-specific protein kinase
(AKT) or proto-oncogene serine/threonine-protein kin-
ase Pim-1 (Pim1), PRAS40 detaches from mTORC1
thereby releasing its inhibitory effects [21, 22]. We have
shown that intrahippocampal injection of naturally
secreted Aβ is sufficient to increase mTOR signaling in
the brains of wild type mice by increasing the phosphor-
ylation of PRAS40 [23].
Pim1 is a kinase member of the proto-oncogene Pim
kinase family [24–27]. Pim1 plays a role in cell survival
and proliferation; hence, its deregulation can easily
transform it to an oncogenic protein. Pim1 has gained
much attention due to its upregulation in a variety of
cancers [28, 29]. Of note, Pim1 knockout mice have no
phenotype [30], suggesting that Pim1 might be a viable
therapeutic target. Crystallographic studies revealed a
unique architecture within the Pim1 secondary struc-
ture, which allowed the synthesis of highly specific
inhibitors [31, 32]. Here, we sought to determine the
effects of reducing Pim 1 activity on AD-like pathology
developed by the 3xTg-AD mice.
Results
Pharmacological characterization of Pim1 inhibitor 1
We have previously shown that the levels of PRAS40
phosphorylated at Thr246 (pPRAS40) are increased in
3xTg-AD mice [23]. To further determine the role of
PRAS40 in AD, we assessed the levels of pPRAS40 in
the inferior frontal gyrus of human AD brains (Table 1).
We found that the levels of pPRAS40 are increased in
human AD brains compared to age-matched controls
(Fig. 1). We then sought to determine the effects of
reducing PRAS40 phosphorylation on the AD-like path-
ology in 3xTg-AD mice. To achieve our goal, we targeted
Pim1, a kinase known to phosphorylate PRAS40 [33].
Several Pim1 kinase inhibitors are commercially available,
and some are currently in clinical trial for the treatment of
cancer (ClinicalTrials.gov Identifier: NCT00848601). The
commercially available Pim1 inhibitor, 3-Cyano-4-phenyl-
6-(3-bromo-6-hydroxy) phenyl-2 (1H)-pyridone (herein
referred to as Pim1i; Fig. 2a), exhibits highly specific com-
petitive inhibition to Pim1; IC50 50 nM for Pim1 and
2 μM for Pim2 [33]. We have shown that intracranial de-
livery of this inhibitor effectively decreases pPRAS40 [23],
a downstream substrate of Pim1. We first tested Pim1i
bioavailability and measured its brain-to-plasma ratio by
LC-MS/MS analysis. To this end, C57BL/6 mice received
a single dose of 50 mg/kg Pim1i intraperitoneally (i.p.).
We found that maximum plasma concentration of Pim1i
was 32166 ± 11220 ng/mL, which was observed at 1 h post
dose with half-life of 1.02 h (Fig. 2b). Pim1i was also de-
tectable up to 3 h post dose in brain tissue homogenate
samples (Fig. 2c). The maximum brain concentration of
197 ± 48.5 ng/g was observed at 0.5 h post dose.
To determine whether Pim1i engages the target, we
injected C57BL/6 mice with 100 mg/kg i.p. and har-
vested brains at 1, 3, 6, 12 and 24 post injection (n = 5
per time-point). Three additional mice were used as our
baseline. We decided to increase the dose as no toxicity
was detected in mice receiving 50 mg/kg Pim1i. We
found that the levels of pPRAS40 were significantly
different across the different time points (F(6, 26) = 11.09;
p < 0.001; Fig. 2d). A Bonferroni’s multiple comparison
Table 1 Descriptive information of patients whose brain tissue
was utilized to measure pPRAS40 levels. Gel order indicates the
order in which protein samples were loaded in Fig. 1
Age at death Diagnosis MMSE score Braak stage Gel load order
86 AD 16 IV 1
82 AD 23 IV 2
93 CTL 30 I 3
89 CTL 29 II 4
92 CTL 26 III 5
79 CTL 29 II 6
82 AD 19 V 7
78 AD 0 VI 8
87 CTL 28 III 9
91 CTL 27 II 10
87 CTL 26 III 11
75 CTL 29 III 12
95 CTL 26 III 13
88 AD 9 VI 14
78 AD - IV 15
68 AD 0 VI 16
78 CTL 29 III 17
85 AD 23 VI 18
86 AD 20 IV 19
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Fig. 1 Phosphorylated PRAS40 levels are increased in AD patients. a Western blots of proteins extracted from the inferior temporal gyrus of
human control (CTL; n = 10) and AD brains (n = 9). Blots were probed with the indicated antibodies. The descriptive information for each patient
(numbered above the blots) are reported in Table 1. b Quantitative analysis of the blot shows that phosphorylated PRAS40 levels were significantly
higher in AD compared to CTL cases (p = 0.0325). Quantitative analyses of the blots were obtained by normalizing PRAS40 levels to β-Actin, used as a
loading control. Error bars represent mean ± SEM
Fig. 2 Pharmacological profile of Pim1i. a Chemical structure of the Pim1 inhibitor (Pim1i) used in this study. b The Pim1i levels measured in
plasma as a function of time after a single intraperitoneal injection of 50 mg/kg. The maximum plasma concentration of Pim1i was 32166 ±
11220 ng/mL observed at 1 h post dose with half-life of 1.02 h. c Pim1i measured in the brain as a function of time after a single intraperitoneal
injection of 50 mg/kg. Pim1i was also detectable up to 3 h post dose in brain tissue homogenate samples. The maximum brain concentration of
197 ± 48.5 ng/g was observed at 0.5 h post dose. d Pim1i reduced phosphorylated PRAS40 levels up to 24 h after a single intraperitoneal injection
of 100 mg/kg. e Schematic of the experimental design. NonTg and 3xTg-AD mice were injected with either the vehicle or 100 mg/kg Pim1i for
28 days. All animals started behavioral testing in the radial arm water maze task at day 26
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test indicated that pPRAS40 levels at the time points 1,
3, 6, 12 and 24 h were significantly different than time 0,
our baseline control. These data show that brain levels
of pPRAS40 were significantly reduced one hour follow-
ing the Pim1i injections and stayed low for 24 h.
Pim1 inhibition reduces spatial reference and working
memory deficits in 3xTg-AD mice
Given these data, we sought to determine the effects of
chronic administration of the Pim1i at a dosage of
100 mg/kg on the AD-like pathology in 3xTg-AD mice.
To this end, we used 7-month-old female 3xTg-AD and
non-transgenic (NonTg) mice. At this age, 3xTg-AD
mice have mild cognitive deficits, which are associated
with high soluble Aβ and tau levels [34]. Mice were ran-
domly assigned to one of the following groups: 3xTg-AD
Vehicle (Veh), NonTg Veh, 3xTg-AD Pim1i, NonTg
Pim1i (n = 14/group) and received daily i.p. injections of
Pim1i or vehicle for 28 days (Fig. 2e).
We first assessed body weight of the mice at the be-
ginning of treatment and found that the average body
weight was 24.21 ± 0.635 g for NonTg mice and 31.46 ±
1.427 g for 3xTg-AD mice. The analysis of mean weight
revealed a significant main effect of Genotype (F(1, 42) =
36.624, p < 0.0001), indicating that 3xTg-AD mice
weighed significantly more than NonTg mice. Similarly,
3xTg-AD mice (28.28 ± 1.05 g) weighed more than the
NonTg mice (22.48 ± 0.46 g) at completion of treatment.
The analysis of mean weight in grams revealed a signifi-
cant main effect of Genotype (F(1, 42) = 28.689, p <
0.0001) and Treatment (F(1, 42) = 5.364, p < 0.05), how-
ever no significant Genotype by Treatment interaction
(F(1, 42) = 1.117, p > 0.05). Together, these data indicate
that the Pim1i treated mice weighed less at the end of
treatment compared to the mice on vehicle, and this dif-
ference was independent of genotype. Notably, during
the 28 days of treatment, we lost mice in all four groups.
The total numbers of mice that did not show any overt
toxicity and were tested behaviorally are as follows:
3xTg-AD Veh (n = 13), NonTg Veh (n = 12), 3xTg-AD
Pim1i (n = 7), NonTg Pim1i (n = 13).
To determine the effect of 28 days of the Pim1i on
spatial reference and working memory, we tested all sub-
jects on an 8-arm radial arm water maze (RAWM) task.
Mice were tested for two consecutive days: on day one,
mice received 15 trials, with trials alternating between
visible and hidden platform. On day 2, mice received 15
additional trials but the platform was kept hidden
throughout the trials. Entry into an incorrect arm was
scored as a spatial reference error. Reentry into a previ-
ously visited arm within the trial was considered a work-
ing memory error. The number of errors were averaged
by block, with each block being equivalent to three trails.
Using a mixed model ANOVA, we first examined mean
incorrect errors between day 1 and 2 to assess learning.
We found a significant effect of Genotype (F(1,42) =
13.610; p < 0.01), Treatment (F(1,42) = 18.790, p < 0.0001),
day (F(1, 42) = 107.868, p < 0.0001) and a trend in Genotype
by Treatment interaction (F(1, 42) = 3.755, p = 0.0594;
Fig. 3a). Specifically, all groups showed a significant reduc-
tion in incorrect errors between day 1 and day 2, indicat-
ing that all groups significantly learned the task.
We next analyzed the number of errors during the
probe trials (day 2). For reference errors, we found a sig-
nificant effect of Block (F(4, 42) = 3.882, p < 0.005, Fig. 3b),
Genotype (F(1, 42) = 8.126, p < 0.01), Treatment (F(1, 42) =
18.105, p < 0.001) and a significant Genotype by Treat-
ment interaction (F(1, 42) = 4.496, p < 0.05). Post hoc test
with Bonferroni’s correction indicated that 3xTg-AD
Veh mice committed a higher number of reference er-
rors throughout the 5 blocks of testing when compared
to the NonTg Veh group (p < 0.05; Fig. 3b for errors
across each block; 2C for mean total errors). Notably,
3xTg-AD Pim1i mice made significantly fewer errors
compared to 3xTg-AD Veh treated mice, indicating im-
proved spatial reference memory (p < 0.01). Further-
more, 3xTg-AD Pim1i mice performed as well as NonTg
Veh mice (p > 0.05), illustrating a full rescue of spatial
reference memory. Interestingly, NonTg mice injected
with Pim1i made significantly fewer errors than the vehicle
treated NonTg mice (p < 0.05). These results show that
28 days of Pim1i administration is sufficient to normalize
the spatial reference memory deficits in 3xTg-AD mice to
NonTg levels, and to improve performance in NonTg mice.
We then examined reentry errors into a previously en-
tered arm within a trial, which indicate working memory
errors. When we compared the mice performance between
the two days of training, we found a significant effect of
Genotype (F(1, 42) = 8.045, p = 0.01), Treatment (F(1, 42) =
10.381, p < 0.01), day (F(1, 42) = 13.693, p < 0.001), and a
Genotype by Treatment interaction (F(1, 42) = 4.390, p <
0.05; Fig. 3d). Notably, 3xTg-AD Veh mice had the same
number of working memory errors between day 1 and day
2 (p > 0.05), indicating that although they decreased the
number of reference memory errors, they continued to
commit working memory errors on day 2. All other groups
show a decrease in working memory errors between day 1
and day 2. These data indicate that 3xTg-AD Pim 1i mice
performed significantly fewer working memory errors
compared to 3xTg-AD Veh. During the probe trials (day
2), we found a significant effect of Genotype (F(1, 42) =
5.255, p < 0.05), Treatment (F(1, 42) = 10.131, p < 0.01), and
Genotype by Treatment interaction (F (1, 42) = 4.496, p <
0.05; Fig. 3e). Post hoc test with Bonferroni’s correction
indicated that 3xTg-AD Veh mice committed a higher
number of working memory errors throughout the 5
blocks of testing when compared to the NonTg-AD Veh
mice (p = 0.0147, Fig. 3e for errors across each block; 3f for
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mean total errors). Pim1i significantly reduced the number
of working memory errors in 3xTg-AD mice compared to
3xTg-AD Veh mice (p < 0.05). Indeed, the number of work-
ing memory errors made by 3xTg-AD Pim1i mice were not
statistically significant from errors made by NonTg Veh
mice (p > 0.05). Collectively, these results show that 28 days
of the Pim1 inhibitor is sufficient to reduce spatial refer-
ence and working memory deficits in 3xTg-AD mice.
“Chaining” is a commonly used search strategy to
find the platform in the RAWM [35]. This method
does not require use of spatial cues and instead con-
sists of sequential arm visits until the platform is
found. To further determine the nature of the cogni-
tive impairment in 3xTg-AD mice, we examined the
use of a chaining strategy for navigation of the maze
during the day 2 probe trials. For this analysis, a
chaining event was defined as three consecutive arm
entries in an anticlockwise or clockwise direction, an
operational definition used by [35]. The percentage of
chaining events committed per group were analyzed
using a chi-square test. We found that 3xTg-AD Veh
mice show a significantly higher number of chaining
events compared to both NonTg groups and 3xTg-AD
Pim1i treated group (X2 = 7.8045, p < 0.01, Fig. 3g-h).
These data suggest that Pim1 inhibition reduces the
usage of the chaining search strategy in 3xTg-AD
mice.
Pim1 inhibition lowers Aβ levels and hippocampal CP13
immunoreactivity in 3xTg-AD mice
At the end of the behavioral testing, mice were sacrificed
and their brains were used for neuropathological and
Fig. 3 Pim1 inhibition reduces spatial reference and working memory deficits in 3xTg-AD mice. NonTg Veh (n = 13), 3xTg-AD Veh (n = 13), NonTg
Pim1i (n = 12), 3xTg-AD Pim1i (n = 7) were tested in the radial arm water maze (RAWM). a Average reference memory errors on day 1 and day 2
RAWM task. All groups show a decrease in total errors in day 2 indicating learning (F(1, 42) = 107.868, p < 0.0001). b Average reference memory
errors across the 5 blocks of testing of day 2 (1 block = 3 trials). 3xTg-AD Veh mice committed a higher number of reference errors throughout
the 5 blocks of testing compared to all the other groups. c Mean total errors of day 2. d Working memory errors on day 1 and day 2. Working
memory errors are defined as a reentry into a previously visited arm. 3xTg-AD Veh mice had the same number of working memory errors
between day 1 and day 2 (p > 0.05), whereas all the other groups showed significant learning between the two days. e Average working
memory errors across the 5 blocks of testing of day 2. 3xTg-AD Veh mice commit a higher number of working memory errors throughout the 5 blocks
of testing compared to the other three groups. f. Mean working memory errors during day 2. g Pim1i significantly reduces the percentage of 3xTg-AD
mice using a hippocampal-independent default strategy to find the hidden platform, known as chaining. The panel illustrates the percentage of mice
committing chaining events between all groups. h The panel illustrates the percentage of animals that committed chaining events between
the four groups. Pim 1i significantly reduced the percentage of chaining committed by the 3xTg-AD mice (X2 = 7.8045, p < 0.01). Error bars
represent mean ± SEM
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biochemical assessment. To determine whether periph-
eral administration of Pim1i reached the brain, we used
sandwich enzyme linked immunosorbent assay to meas-
ure the levels of pPRAS40 at Thr246, as this epitope is
directly phosphorylated by Pim 1 [33]. We found a sig-
nificant effect for Genotype (F(1, 20) = 4.501, p < 0.05),
Treatment (F(1, 20) = 36.593, p < 0.0001), and a non-
significant Genotype by Treatment interaction (F(1, 20) =
1.767, p > 0.05; Fig. 4a). The effect of genotype indicated
that 3xTg-AD mice show higher levels of pPRAS40 than
NonTg mice. Interestingly, the treatment effect reveals
that both 3xTg-AD and NonTg Pim1i mice have a re-
duced pPRAS40 level. Together, these data further con-
firm that Pim1i crosses the blood brain barrier and
decreases the levels of brain pPRAS40.
One of the key neuropathological features of AD is the
accumulation of extracellular Aβ plaques [2]. Aβ peptides
consist of 36–43 amino acids, where Aβ40 and Aβ42 are
the more abundant Aβ species. Aβ42 is more prone to
aggregation and toxicity than the Aβ40 species [2]. We im-
munostained sections from 3xTg-AD Veh (n = 6) and
3xTg-AD Pim1i (n = 5) mice with an Aβ42-specific anti-
body and found that Aβ42 immunoreactivity was signifi-
cantly reduced in the brains of 3xTg-AD mice injected
with Pim1i (Fig. 4b-c). Quantitative analysis of the overall
Aβ42 load indicated a significant decrease of 45.2 % in the
brain of 3xTg-AD Pim1i compared with 3xTg-AD mice
(t (10) = 8.419, p < 0.05; Fig. 4d). We next measured Aβ
levels by sandwich ELISA and found that both soluble
and insoluble Aβ40 levels were significantly lower in
3xTg-AD Pim1i mice compared with 3xTg-AD Veh
mice (soluble Aβ40: t(10) =2.442, p < 0.05; insoluble
Aβ40: t(10) = 2.681, p = 0.0230; Fig. 5a-b). Furthermore,
both soluble and insoluble levels of Aβ42 were signifi-
cantly lower in 3xTg-AD Pim1i compared to 3xTg-AD
Veh mice (soluble Aβ42: t(10) = 2.404, p = 0.0371; insol-
uble Aβ42: t(10) = 3.932, p < 0.01; Fig. 5c-d).
Another hallmark pathology associated with AD is the
accumulation of neurofibrillary tangles made of hyperpho-
sphorylated tau [2]. To determine the effects of Pim1
inhibition on tau pathology, we first immunostained sec-
tions from 3xTg-AD Veh and 3xTg-Pim1-inh1 mice with
CP13, an antibody that recognizes tau phosphorylated at
serine 202. We found that CP13 immunoreactivity was re-
duced in 3xTg-AD Pim1i compared with 3xTg-AD mice
(Fig. 6a-b). Quantitative analysis indicated that CP13 im-
munoreactivity was significantly decreased by 38 % in the
brain of 3xTg-AD Pim1i compared with 3xTg-AD Veh
mice (t (10) = 2.785, p < 0.05; Fig. 6c). To further assess the
tau pathology, we measured tau levels by western blot
Fig. 4 Pim1i decreases Aβ pathology. a The graph shows the phosphorylated levels of PRAS40 levels after 28 days of treatment, measured by
sandwich ELISA. The Pim1 inhibitor significantly reduced the pPRAS40 levels of both the 3xTg-AD and NonTg mice as evident by a significant
effect of treatment (F(1, 42) = 36.593, p < 0.0001). b Representative microphotographs of brain sections from 3xTg-AD mice stained with an Aβ42
specific antibody (Millipore, catalog number AB5078P). d Quantitative analysis of Aβ42 immunoreactivity by unpaired t-test reveals that 3xTg-AD
mice treated with Pim1i had significantly fewer plaques compared to 3xTg-AD mice treated with vehicle (t(8) = 8.419, p < 0.05). Error bars
represent mean ± SEM
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using antibodies against total and phosphorylated tau. We
found that the levels of total human tau (measured by
HT7) were not significantly different between the Veh and
Pim1i-treated groups (p > 0.05; Fig. 6d-e). In contrast, we
found a main effect of Genotype for CP13 levels (F(1,15) =
4.563, p < 0.05; Fig. 6d, f ). Post hoc analyses indicated that
3xTg-AD mice had significantly higher levels than NonTg
mice. The apparent contradiction between the CP13 data
obtained by immunohistochemistry and by western blot is
likely due to the fact that the immunohistochemistry al-
lows for single cell resolution while the western blot was
done by homogenizing different cell types from different
brain regions. Overall, these results show that Pim1 inhib-
ition reduces hippocampal tau immunoreactivity in 3xTg-
AD mice.
Pim1i increases proteasome activity
Our results indicate that reductions in pPRAS40 via
Pim1 inhibition is sufficient to reduce spatial reference
and working memory deficits in 3xTg-AD mice. These
improvements in cognitive function are associated with
a reduction in Aβ levels and phosphorylated tau immu-
noreactivity. To better elucidate the mechanisms under-
lying these effects, we first assessed mTOR signaling by
measuring the phosphorylation levels of the two major
downstream targets of mTOR: p70S6K1 and 4EBP1.
For the phosphorylation levels of p70S6K1, there were
no significant effects of Genotype (F(1,15) = 4.067, p >
0.05), treatment (F(1,15) = 0.428, p > 0.05), and Genotype
by Treatment interaction (F(1,15) = 1.831, p > 0.05; Fig. 7a-b).
Interestingly for the downstream target 4EBP1, there was a
main effect of Genotype (F(1, 15) = 5.621, p = 0.05;
Fig. 7a, c) where the NonTg mice had increased levels
of phosphorylated 4EBP1 compared to 3xTg-AD mice.
There was no effect of the Pim1i treatment on these
targets.
To further understand what mechanisms may underlie
changes in AD pathology and improvements in behavior,
we assessed autophagy induction and proteasome func-
tion. We focused on these systems as they represent the
two major cellular protein degradation systems and are
known to be involved in the turnover of Aβ and tau
[36]. First, we measured the levels of LC3, Atg3, Atg5,
and Atg12, key proteins involved in autophagy induction
whose levels are routinely used to monitor it [37]. We
found a significant main effect of Genotype (F(1, 15) =
7.238, p < 0.05) but a non-significant effect of Treatment
(F (1, 15) = 2.230, p > 0.05) or Genotype by Treatment inter-
action (F(1, 15) = 0.00042, p > 0.05) for p62 (Fig. 8a-b). In
addition, we found a significant main effect of Genotype
(F(1, 15) = 10.851, p < 0.01) but a non-significant effect of
Treatment (F (1, 15) = 0.266, p > 0.05) and the Genotype by
Fig. 5 Pim1i decreases Aβ levels. Sandwich ELISA measurements of insoluble and soluble Aβ40 and Aβ42 levels in brain extracts from 3xTg-AD
veh (n = 7) and 3xTg-AD Pim1i (n = 5) mice. a, b Soluble and insoluble Aβ42 levels were significantly lower in 3xTg-AD mice injected with Pim1i
(Soluble Aβ40: t(10) =2.442, p < 0.05; insoluble Aβ40: t(10) = 2.681, p < 0.05). c, d Soluble and insoluble Aβ42 levels were significantly lower in 3xTg-AD
mice treated with Pim1i (soluble Aβ42: t(10) = 2.404, p < 0.05; insoluble Aβ42: t(10) = 3.932, p < 0.01). Error bars represent mean ± SEM
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Treatment interaction (F(1, 15) = 1.607, p > 0.05) for Atg3
(Fig. 8a, c). In contrast, the levels of Atg5 and Atg12 were
similar among the four groups (Fig. 8a, d and e).
Next, we used the fluorogenic substrates Bz-VGR-
AMC, Suc-LLVYAMC, and Z-LLE-AMC to measure
trypsin-like, chymotrypsin-like, and caspase-like activ-
ities of the proteasome. We found an effect of Treat-
ment for chymotrypsin-like (F(1, 20) = 10.127, p < 0.05,
Fig. 8f ), trypsin-like (F(1, 20) = 16.18, p < 0.001, Fig. 8g)
and caspase-like (F(1, 20) = 19.804, p < 0.001, Fig. 8h)
activity. This finding indicates that the Pim1 inhibi-
tor increases the activity of the three substrates for
both the 3xTg-AD and NonTg mice over the vehicle
treated groups. This suggests that the reductions in
Aβ pathology and tau immunoreactivity may be ac-
complished by an increase in protein degradation.
Discussion
The incidence of AD is quickly increasing and with
no effective therapeutics to reduce the associated
pathologies, this disorder is bound to have a major
socio-economic impact on our society. The data pre-
sented here unambiguously show that inhibiting
Pim1 activity for 28 days, thereby reducing pPRAS40
levels, has beneficial effects on AD-like pathology in
3xTg-AD mice. Indeed, these data show that
Fig. 6 Reduced Tau pathology in 3xTg-AD Pim1i mice. a, b Representative microphotographs of CA1 hippocampal neurons from 3xTg-AD Veh
and 3xTg-AD Pim1i mice stained with the anti-tau antibody CP13, which recognizes tau phosphorylated at Ser202. c Quantitative analysis of the
CP13 immunoreactivity by unpaired t-test reveals that Pim1i significantly reduced tau immunoreactivity (t(9) = 2.785, p < 0.05). d Representative
western blots of protein extracted from 3xTg-AD Veh, NonTg Veh, 3xTg-AD Pim1i, and NonTg Pim1i mice. Blots were probed with the indicated
antibodies. The HT7 antibody recognizes total human tau and CP13 antibody recognizes tau phosphorylated at Ser202. e, f Quantitative analyses
of the blots. HT7 levels were not significantly different between the two groups (t(9) = 0.558, p > 0.05). For CP13, we found a Genotype effect
(t(9) = 4.563, p < 0.05), revealing higher levels of CP13 in 3xTg-AD mice. Quantitative analyses of the blots were obtained by normalizing the
levels of the protein of interest to β-Actin, used as a loading control. Error bars represent mean ± SEM
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inhibition of Pim1 reduced spatial reference and
working memory errors in 3xTg-AD mice, and im-
proved performance to NonTg levels. This cognitive
improvement was associated with a reduction in hip-
pocampal Aβ pathology and hippocampal tau
immunoreactivity.
PRAS40 is a component of the mTOR complex 1; it
physically binds to mTOR and negatively regulates its
activity [33]. Upon phosphorylation, PRAS40 detaches
from mTOR releasing its inhibitory effects. Indeed, high
levels of pPRAS40 have been associated with high
mTOR activity [8, 33]. Notably, the levels of pPRAS40
are elevated in both humans AD patients and 3xTg-AD
mice [23]. We have previously shown that the increase
in pPRAS40 is due to a buildup in Aβ oligomers [23].
Paradoxically, although we show that Pim1 inhibition
reduces the levels of pPRAS40, the activity of mTOR
appeared unaffected. Indeed, Pim1 inhibition did not
change the phosphorylation levels of p70S6K1 and
4EBP1. These findings suggest that the reduction in Aβ
pathology and hippocampal tau immunoreactivity may
occur through an mTOR independent pathway. To this
end, our data suggest that the mechanism underlying
the reduced AD-like pathology is linked to an increase
in proteasome activity as evident by the changes in the
three proteolytic activities, chymotrypsin-like, trypsin-
like and caspase-like, which comprise the catalytic core
of the proteasome [38–40]. These results are consistent
with previous findings showing that modulation of
pPRAS40 levels alter proteasome function independent
of mTOR activity [41, 42].
Interestingly, the increase in three proteolytic activities
of the proteasome were observed in both the 3xTg-AD
and NonTg mice and were associated with inhibition of
Pim1 and reduced pPRAS40 levels. The increase in pro-
teasome activity suggests an increase in degradation of
Aβ and tau proteins. Proteasome dysfunction has been
linked to AD pathology in both AD patients and mouse
models [43–45]. In particular, studies have shown that
proteasome activity is decreased in the hippocampus,
which is more susceptible to AD pathology, and less in
areas like the cerebellum, where minimal to no changes
in proteasome functions have been detected in AD pa-
tients [43]. To this end, work has found accumulation of
Aβ and tau after direct inhibition of proteasome activity
in the 3xTg-AD mice [45]. Consistent with these obser-
vations, we and others have reported that increased pro-
teasome activity is sufficient to degrade Aβ and relieve
deficits in cognitive function [44, 46, 47].
Diabetes is a major risk factor of AD [48–50]; however,
the molecular pathways linking diabetes to AD remain
elusive. Physiologically, PRAS40 is activated by Pim1
and by phosphatidylinositol 3-kinase/Akt (PI3K/Akt),
which are further regulated by upstream tyrosine kinase
receptor growth factors, including insulin-like growth
factor 1 [51]. To this end, insulin signaling facilitates
PRAS40 phosphorylation at Thr246 [9, 52, 53]. Glucose-
induced hyperphosphorylation of PRAS40 has been im-
plicated in type 2 diabetes [54] and in the progression of
diabetic nephropathy [55]. Higher pPRAS40 levels in-
crease activation of mTORC1 and its downstream tar-
gets [33]. At the same time, both PRAS40
phosphorylation and mTOR activity are increased in AD
patients and in AD animal models, and contribute to the
buildup of Aβ and tau [6, 10, 15, 56]. While further
studies are needed, these data suggest that PRAS40
Fig. 7 Pim 1i does not alter mTORC1 signaling. a Representative
western blots of the phosphorylated levels of downstream mTORC1
targets 4EB-P1, p70S6K1 and β-Actin control. b, c Quantitative analyses
of the blots show. We found no changes in p-p70S6K1 levels. In
contrast, we found that the NonTg groups had higher levels of
p4EBP1 compared to the 3xTg-AD groups (F(1, 15) = 5.621, p < 0.05).
Quantitative analyses of the blots were obtained by normalizing the
levels of the protein of interest to β-Actin, used as a loading control.
Error bars represent mean ± SEM
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phosphorylation might represent a molecular link be-
tween diabetes and AD.
Conclusions
In conclusion, our data highlight the commercially
available Pim1 inhibitor as a potential therapeutic to
reduced AD-neuropathology and associated cognitive
deficits by decreasing elevated pPRAS40 levels and in-
creasing proteasome activity in the 3xTg-AD mouse
model.
Methods
Human and mouse tissue
Human tissue was obtained from the Brain and Body
Donation Program at the Banner Sun Health Research
Institute, an ongoing longitudinal clinicopathological
study of normal aging and neurodegenerative disorders
[57]. Human cases were selected randomly by personnel
of the Brain and Body Donation program among the tis-
sue available. Groups were matched based on their clin-
ical and neuropathological phenotype. The generation of
the 3xTg-AD mice used in the current study has been
described previously [34]. All mice were housed 4–5 per
cage at 23 °C, kept on a 12 h light/dark cycle, and were
given ad libitum access to food and water. In our colony
of 3xTg-AD mice, males show a large neuropathological
variability, even between littermates. In contrast, female
3xTg-AD mice do not show such large variability and
their phenotype changes as a function of age in a pre-
dictable manner. Therefore, only female mice were
used for the experiments described here. All animal
procedures were approved by the Arizona State Univer-
sity Institutional Animal Care and Use Committee
(IACUC). All behavioral and experiments were performed
Fig. 8 Pim 1i increases proteasome function. a Representative western blots of protein extracted from treated and untreated 3xTg-AD and NonTg
mice. Blots were probed with the indicated antibodies. b Quantitative analyses of the p62 blots show that p62 levels are reduced in both 3xTg-AD
groups compared to the NonTg groups, as indicated by a significant main effect of Genotype (F(1, 15) = 7.238, p < 0.05). These p62 changes were
independent of Pim1 inhibition. c. Quantitative analyses of the ATG3 blots show that the ATG3 levels are reduced in both 3xTg-AD groups compared
to the NonTg groups, as indicated by a significant main effect of Genotype (F(1, 15) = 10.851, p < 0.01). d, e Quantitative analyses of the ATG5 and
ATG12 blots indicate no significant difference among the four groups. f-h Proteasome analyses of proteins extracted from the brains of the four groups
of mice revealed significant main effects of treatment for chymotrypsin-like (F(1, 20) = 10.127, p < 0.05), trypsin-like (F(1, 20) = 16.18, p < 0.001),
and caspase-like (F(1, 20) = 19.804, p < 0.001) activities. Quantitative analyses of the blots were obtained by normalizing the levels of the
protein of interest to β-Actin, used as a loading control. Error bars represent mean ± SEM
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with the experimenters blind to the genotype and
treatment.
Pim1i analysis
Absorption Systems (Philadelphia, PA) performed the
detection of the Pim1 inhibitor in the blood and brain of
C57BL/6 mice injected with a dosage of 50 mg/kg. Stan-
dards were prepared in C57BL/6 mouse plasma contain-
ing sodium heparin as an anticoagulant, or in blank
homogenized C57BL/6 mouse brain. The calibration
curve was prepared to concentrations of 1000, 500, 250,
100, 50, 10, 5, and 2.5 ng/mL by serial dilution. Standard
samples were treated identically to the study samples.
Plasma and brain homogenate samples were extracted
via acetonitrile precipitation on a Tomtec Quadra 96-
Model 320 liquid handling system in a 96-well plate for-
mat. The procedure for sample extraction were as fol-
lows; (1) Add 55 μL of samples or standards into 2 mL
polypropylene 96-well plate; (2) Using the Tomtec, add
50 μL of sample to 150 μL of acetonitrile (containing
100 ng/mL warfarin as an internal standard) that has
been pre-loaded onto a Sirocco Protein Precipitation
plate (Waters Corp.); (3) Using the Tomtec, mix the
samples via air aspiration; (4) Apply vacuum and Cap
for analysis.
8-arm radial arm water maze
The radial arm water maze (RAWM) task is utilized to
assess hippocampal-dependent spatial reference and
working memory [58, 59]. The task was performed in a
black maze of 66 cm in diameter, made of black ABS
Plexiglas. The maze consists of eight radiating arms,
which were filled with water kept at 23.5 °C. The water
was made opaque with nontoxic white paint. An 8 cm
wide platform was kept 1.5 cm under the surface of the
water at the end of the arm and was invisible to mice. A
white ABS pipe 2.5 cm wide and plastic flag were used
for visible trials. The location of the extramazal cues and
platform were kept in the same place in space through-
out the testing period. Mice were tested between 9:00
A.M. and 3:00 P.M. and started from a different pseudo-
randomly chosen arm for each of the 15 daily trials. On
the first trial of day one, mice were to locate the plat-
form with the aid of a flag attached to the platform,
making this trial visible. On trial 2, the flag was re-
moved, forcing the mice to use extramazal cues (located
throughout the room) to find the escape platform. The
proceeding trials alternated from visible to hidden until
12 trials were completed, followed by three hidden trials
to end day one. On day two, mice received 15 trials,
which were all performed with the hidden platform. If
mice failed to find the platform within 60 s, they were
gently guided to the platform location and allowed to
stay on it for 10 s. At the end of each trial, mice were
placed in a warm holding cage for 25 s before starting
the next trial. A video camera recorded each mouse, and
the experimenter, which was blind to the genotype and
treatment scored the entries into arms. The dependent
variables for learning were incorrect arm entries and re-
entries in day one versus two, with a decrease number of
errors in day 2 versus day 1 interpreted as learning. The
dependent measures for day 2 were incorrect arm entries
(reference memory errors), reentries (working memory
errors) and chaining events (3 consecutive arm entries
into adjacent arms).
Protein extraction
Human and mouse proteins were prepared as previously
described [10]. Briefly, mice were sacrificed and their
brains were removed and cut in half along the medial
longitudinal/sagittal fissure. One hemisphere of the brain
was post-fixed in 4 % paraformaldehyde for 48 h and
used for immunohistochemical evaluation. The other
hemisphere was flash-frozen on dry ice and used for bio-
chemical experiments and stored at −80 °C. The frozen
mouse hemispheres as well as 0.1 g of human inferior
frontal gyrus tissue were mechanically homogenized in
ice-cold T-PER protein extraction buffer (Thermo Fisher
Scientific) containing complete protease inhibitor
(Roche) and phosphatase inhibitor (Life Technologies).
Brain homogenates were ultracentrifuged at 100,000 × g
for 1 h at 4 °C. The supernatant was recovered and
stored at −80 °C until used for western blots and for
both pPRAS40 and soluble Aβ levels by ELISA. The pel-
let was re-suspended in 70 % formic acid, mechanically
homogenized, and centrifuged as described above. The
supernatant of this second centrifugation was recovered
and stored at −80 °C until used as the insoluble fraction
for ELISA experiments.
Western blot
Western blots were performed under reducing condi-
tions using precast Novex gels (Life Technologies). Pro-
teins were transferred to nitrocellulose membranes
(iBlot2, Life Technologies) followed by incubation for
60 min in 5 % nonfat powdered milk (Great Value) in
Tris-buffered saline with Tween (TBST: 0.1 M Tris,
0.15 M NaCl, and 0.1 % Tween 20). Primary antibodies
specific to the experiment were then applied overnight
at 4 °C in 5 % milk in TBST. The following day, blots
were washed in TBST three times for 15 min and then
incubated in the appropriate fluorescent secondary anti-
body for 1 h at room temperature. The blots were then
washed as describe above, and imaged/quantified using a
LICOR Odyssey CLx (LI-COR Biosciences) attached to a
Dell computer (OptiPlex 7010) running Windows 7 and
Image Studio (version 1.0.11, LI-COR Biosciences).
Quantitative analyses of the western blots were obtained
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by normalizing the intensity of the protein of interest
with its loading control, β-actin.
Histology
For immunohistochemistry analysis, hemispheres were
fixed in 4 % paraformaldehyde for 48 h. Tissue was then
sectioned (50 μm thick) using a sliding vibratome, and
stored in 0.02 % sodium azide in PBS. The endogenous
peroxidase activity was quenched with 3 % H2O2 in
10 % methanol for 30 min. For Aβ42 staining, tissue was
incubated for 7 min in 95 % formic acid to retrieve the
epitope. Then, tissue was incubated overnight at 4 °C
with an appropriate primary antibody. Sections were
washed to remove excess primary antibody and incubated
in the appropriate secondary antibody for 1 h at room
temperature. Excess secondary antibody was washed and
sections were developed with diaminobenzidine substrate
using the avidin– biotin horseradish peroxidase system
(Vector Labs).
ELISA
The commercially available sandwich ELISA assay by
Cell Signaling Technology was used to assess pPRAS40
levels. Fractions of brain homogenates were processed
and read in a plate reader (Bio Tek) at 450 nm in pre-
coated, flat-bottom 96-well plates according to the kit’s
instructions. The concentration of pPRAS40 (picograms
per milliliter of sample) present in the homogenate was
the dependent variable used for statistical analysis. We
used the Life Technologies ELISA kit to assess Aβ40 and
Aβ42 levels. Briefly, soluble or insoluble fractions of
brain tissue homogenates were processed and read in a
plate reader (BioTek) at 450 nm in precoated, flat-
bottom 96-well plates according to the kit’s instructions.
The range of Aβ detection was between 10 and 1000 pg/
ml. For each assay kit, cross-reactivity with other species
of Aβ, APP, or tau was negligible when concentrations
were <10 ng/ml. The concentration of Aβ (picograms
per milliliter of sample) present in the homogenate was
the dependent variable used for statistical analysis.
Proteasome activity
Proteasome activity was assessed as previously described
[10]. Briefly, 10 μl of brain homogenate were incubated
with proteasomal substrates Suc-LLVY-AMC, Bz-VGR-
AMC, and Z-LLE-AMC (Enzo Life Sciences), which
probe for chymotrypsin-like, trypsin-like, and caspase-
like activities, respectively. Reactions were performed in
200 μl of assay buffer (25 mM HEPES, pH 7.5, 0.5 mM
EDTA, 0.05 % NP-40) using black 96-well plates. Sub-
strates were added immediately before readings. Kinetic
readings were taken at 37 °C every 1.5 min for 60 min
(excitation, 360 nm; emission, 460 nm) using the Syn-
ergy HT multimode microplate reader with Gen5
software (BioTek). Readings were normalized to total
protein concentrations assayed via a Coomassie Protein
Assay Kit (Bradford, Thermo Scientific) following the
manufacturer’s instructions.
Antibodies
The following antibodies were purchased from Cell Sig-
naling Technology: pP70S6K1 Thr389 (dilution 1:1000,
catalog #9204), p4EB-P1 Ser65 (dilution 1:1000, catalog
#9451) β-actin (dilution 1:10000, catalog #3700), Atg3
(dilution 1:1000, catalog #3415), Atg5 (dilution 1:1000,
catalog #2630), Atg12 (dilution 1:1000, catalog #2010).
The following antibodies were purchased from Millipore:
anti-Aβ42 (dilution 1:200, catalog #AB5078P). Thermo
Fisher Scientific provided HT7 (dilution 1:3000, catalog
#MN1000). CP13 (dilution 1:1000) was a gift from Peter
Davies.
Statistical analyses
Examination of the data evaluated via mixed (repeated
measures) model ANOVAs revealed no violations of any
assumptions that would warrant using a statistical test
other than the ones described. Assumptions were tested
via conventional methods using SPSS 18 (IBM). These
included normality (Shapiro–Wilk, p’s 0.10), homogen-
eity of variance (Levene’s test, p’s 0.05), and sphericity
(Mauchly’s test, p’s 0.26). Learning data which included
incorrect (reference) errors and working memory errors
were analyzed by a two-way mixed ANOVA, followed by
Bonferroni’s corrected post hoc tests using Statview for
Windows Version 5.0.1. Chaining data were analyzed
using a 2x2 contingency Chi-square table. Proteasome
activity was analyzed by an omnibus two-way ANOVA.
A two-tailed unpaired t test was used to analyze select
pairwise comparisons (e.g., Western blots in human
cases and histology, ELISA for soluble and insoluble Aβ
in 3xTg-AD mice), as specified in the results section.
These analyses were performed using Stat view for Win-
dows Version 5.0.1. A priori power analysis was not per-
formed but our sample sizes are similar to those
reported in previously published papers (Ma et al., 2013;
Caccamo et al., 2014; Caccamo et al., 2015). Where
representative images are shown, statistical analyses
were performed on the entire sample as indicated in
each figure legend.
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